Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB

Journal of Inflammation

Volumn 7, Issue , 2010, Pages

  Miguel Carrasco, José L ^a   Zambrano, Sonia ^a   Blanca, Antonio J ^a   Mate, Alfonso ^a   Vázquez, Carmen M ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PROTEIN P22;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEART LEFT VENTRICLE; HYPERTENSION; INFLAMMATION; MALE; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TRANSCRIPTION INITIATION;

ANIMALIA; RATTUS;

EID: 77953025722     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-7-21     Document Type: Article

References (62)

1. Temporal characteristics of cardiomyocyte hypertrophy in the spontaneously hypertensive rat. D Bell EJ Kelso CC Argent GR Lee AR Allen BJ McDermott, Cardiovasc Pathol 2004 13 71 78 10.1016/S1054-8807(03)00135-2 15033155
2. The electrophysiological characteristics of hypertrophied ventricular myocytes from the spontaneously hypertensive rat. P Brooksby AJ Levi JV Jones, J Hypertens 1993 11 611 622 10.1097/00004872-199306000-00005 8397240
3. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. H Matsuoka M Nakata K Kohno Y Koga G Nomura H Toshima T Imaizumi, Hypertension 1996 27 14 18 8591877
4. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. F Simko O Pechanova V Pelouch K Krajcirovicova M Mullerova K Bednarova M Adamcova L Paulis, J Hypertens 2009 27 Suppl 6 5 10 10.1097/01.hjh.0000358830.95439.e8 19633453
5. Hypertension-induced end-organ damage: A new transgenic approach to an old problem. FC Luft E Mervaala DN Muller V Gross F Schmidt JK Park C Schmitz A Lippoldt V Breu R Dechend D Dragun W Schneider D Ganten H Haller, Hypertension 1999 33 212 218 9931107
6. Inflammation in hypertension. C Savoia EL Schiffrin, Curr Opin Nephrol Hypertens 2006 15 152 158 16481882
7. Inflammation of different tissues in spontaneously hypertensive rats. L Sun YH Gao DK Tian JP Zheng CY Zhu Y Ke K Bian, Sheng Li Xue Bao 2006 58 318 323 16906331
8. The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. JL Miguel-Carrasco A Mate MT Monserrat JL Arias O Aramburu CM Vazquez, Am J Hypertens 2008 21 1231 1237 10.1038/ajh.2008.271 18787523
9. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. U Sharma NE Rhaleb S Pokharel P Harding S Rasoul H Peng OA Carretero, Am J Physiol Heart Circ Physiol 2008 294 1226 H1232 10.1152/ajpheart.00305.2007 18178715
10. Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. Y Sun A Ratajska G Zhou KT Weber, J Lab Clin Med 1993 122 395 403 8228553
11. Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. AR Brasier M Jamaluddin Y Han C Patterson MS Runge, Mol Cell Biochem 2000 212 155 169 10.1023/A:1007133710837 11108147
12. Regulating the regulator: NF-kappaB signaling in heart. G Hall JD Hasday TB Rogers, J Mol Cell Cardiol 2006 41 580 591 10.1016/j.yjmcc.2006.07.006 16949095
13. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. M Takemoto K Egashira H Tomita M Usui H Okamoto A Kitabatake H Shimokawa K Sueishi A Takeshita, Hypertension 1997 30 1621 1627 9403592
14. Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction. SP Didion DA Kinzenbaw LI Schrader Y Chu FM Faraci, Hypertension 2009 54 619 624 10.1161/HYPERTENSIONAHA.109.137158 19620507
15. Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalapril. MM Ciulla R Paliotti A Esposito C Cuspidi ML Muiesan EA Rosei F Magrini A Zanchetti, J Hypertens 2009 27 626 632 10.1097/HJH.0b013e3283232838 19262230
16. Role of endothelium and nitric oxide in experimental hypertension. H Vapaatalo E Mervaala ML Nurminen, Physiol Res 2000 49 1 10 10805399
17. Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril. O Pechanova I Bernatova V Pelouch F Simko, J Mol Cell Cardiol 1997 29 3365 3374 10.1006/jmcc.1997.0566 9441842
18. Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: modulation of proinflammatory signals. W Gonzalez V Fontaine ME Pueyo N Laquay D Messika-Zeitoun M Philippe JF Arnal MP Jacob JB Michel, Hypertension 2000 36 103 109 10904020
19. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. MA Hernandez-Presa C Bustos M Ortego J Tunon L Ortega J Egido, Am J Pathol 1998 153 1825 1837 9846973
20. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. EA Rosei D Rizzoni ML Muiesan I Sleiman M Salvetti C Monteduro E Porteri, J Hypertens 2005 23 435 444 10.1097/00004872-200502000-00027 15662233
21. The inhibitory effect of alacepril, an angiotensin-converting enzyme inhibitor, on endothelial inflammatory response induced by oxysterol and TNF-alpha. M Shimozawa Y Naito H Manabe K Uchiyama K Katada M Kuroda N Nakabe N Yoshida T Yoshikawa, Redox Rep 2004 9 354 359 10.1179/135100004225006876 15720832
22. Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. WW Brooks OH Bing KG Robinson MT Slawsky DM Chaletsky CH Conrad, Circulation 1997 96 4002 4010 9403625
23. Angiotensin-converting enzyme inhibitors: a new mechanism of action. H Peng OA Carretero N Vuljaj TD Liao A Motivala EL Peterson NE Rhaleb, Circulation 2005 112 2436 2445 10.1161/CIRCULATIONAHA.104.528695 16216963
24. The ACE inhibitors enalapril and captopril modulate cytokine responses in Balb/c and C57Bl/6 normal mice and increase CD4(+)CD103(+)CD25(negative) splenic T cell numbers. D Albuquerque J Nihei F Cardillo R Singh, Cell Immunol 2010 260 92 97 10.1016/j.cellimm.2009.09.006 19854435
25. Effects of the angiotensin converting enzyme inhibitor captopril on experimental autoimmune encephalomyelitis. CS Constantinescu E Ventura B Hilliard A Rostami, Immunopharmacol Immunotoxicol 1995 17 471 491 10.3109/08923979509016382 8576541
26. Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy. SC Tang JC Leung LY Chan AA Eddy KN Lai, Kidney Int 2008 73 288 299 10.1038/sj.ki.5002674 18033243
27. Effects of captopril on interleukin-6, leukotriene B(4), and oxidative stress markers in serum and inflammatory exudate of arthritic rats: evidence of antiinflammatory activity. AM Agha M Mansour, Toxicol Appl Pharmacol 2000 168 123 130 10.1006/taap.2000.8985 11032767
28. The effect of angiotensin-converting enzyme inhibitors on experimental colitis in rats. N Jahovic F Ercan N Gedik M Yuksel G Sener I Alican, Regul Pept 2005 130 67 74 10.1016/j.regpep.2005.03.009 15908024
29. Captopril suppresses inflammation in endotoxin-induced uveitis in rats. I Ilieva K Ohgami XH Jin Y Suzuki K Shiratori K Yoshida S Kase S Ohno, Exp Eye Res 2006 83 651 657 10.1016/j.exer.2006.03.005 16698015 (Pubitemid 43902786)
30. Effect of spironolactone and captopril on nitric oxide and S-nitrosothiol formation in kidney of L-NAME-treated rats. O Pechanova J Matuskova D Capikova L Jendekova L Paulis F Simko, Kidney Int 2006 70 170 176 10.1038/sj.ki.5001513 16710350
31. Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues. EM de Cavanagh F Inserra L Ferder CG Fraga, Am J Physiol Regul Integr Comp Physiol 2000 278 572 R577 10712274
32. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension. H Peng OA Carretero TD Liao EL Peterson NE Rhaleb, Hypertension 2007 49 695 703 10.1161/01.HYP.0000258406.66954.4f 17283252
33. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. P Chomczynski N Sacchi, Nat Protoc 2006 1 581 585 10.1038/nprot.2006.83 17406285
34. Effects of captopril on the renin angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats. RJ Bolterman MC Manriquez MC Ortiz Ruiz LA Juncos JC Romero, Hypertension 2005 46 943 947 10.1161/01.HYP.0000174602.59935.d5 16087785
35. Regulation of sodium-glucose cotransporter SGLT1 in the intestine of hypertensive rats. A Mate A Barfull AM Hermosa L Gomez-Amores CM Vazquez JM Planas, Am J Physiol Regul Integr Comp Physiol 2006 291 760 R767 16690767
36. Comparative effects of captopril and l-carnitine on blood pressure and antioxidant enzyme gene expression in the heart of spontaneously hypertensive rats. JL Miguel-Carrasco MT Monserrat A Mate CM Vazquez, Eur J Pharmacol 2010 632 65 72 10.1016/j.ejphar.2010.01.017 20123095
37. Lack of beneficial metabolic effects of quercetin in adult spontaneously hypertensive rats. M Romero R Jimenez B Hurtado JM Moreno I Rodriguez-Gomez R Lopez-Sepulveda A Zarzuelo F Perez-Vizcaino J Tamargo F Vargas J Duarte, Eur J Pharmacol 2010 627 242 250 10.1016/j.ejphar.2009.11.006 19903466
38. Pro-inflammatory cytokines in patients with essential hypertension. AC Peeters MG Netea MC Janssen BJ Kullberg JW Van der Meer T Thien, Eur J Clin Invest 2001 31 31 36 10.1046/j.1365-2362.2001.00743.x 11168436
39. Induction of higher expression of IL-beta and TNF-alpha, lower expression of IL-10 and cyclic guanosine monophosphate by pulmonary arterial hypertension following cardiopulmonary bypass. Y Lei J Zhen XL Ming HK Jian, Asian J Surg 2002 25 203 208 12376215
40. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. D Sanz-Rosa MP Oubina E Cediel HN de Las O Vegazo J Jimenez V Lahera V Cachofeiro, Am J Physiol Heart Circ Physiol 2005 288 111 H115 10.1152/ajpheart.01061.2003 15308481
41. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. B Schieffer C Bunte J Witte K Hoeper RH Boger E Schwedhelm H Drexler, J Am Coll Cardiol 2004 44 362 368 10.1016/j.jacc.2004.03. 065 15261932
42. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. T Ito T Okada H Miyashita T Nomoto M Nonaka-Sarukawa R Uchibori Y Maeda M Urabe H Mizukami A Kume M Takahashi U Ikeda K Shimada K Ozawa, Circ Res 2007 101 734 741 10.1161/CIRCRESAHA.107.153023 17673672
43. Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis. M Koyanagi K Egashira S Kitamoto W Ni H Shimokawa M Takeya T Yoshimura A Takeshita, Circulation 2000 102 2243 2248 11056100
44. Interleukin-10 protects nitric oxide-dependent relaxation during diabetes: role of superoxide. CA Gunnett DD Heistad FM Faraci, Diabetes 2002 51 1931 1937 10.2337/diabetes.51.6.1931 12031983
45. Protective role of interleukin-10 in atherosclerosis. Z Mallat S Besnard M Duriez V Deleuze F Emmanuel MF Bureau F Soubrier B Esposito H Duez C Fievet B Staels N Duverger D Scherman A Tedgui, Circ Res 1999 85 17 e24 10521249
46. Comparison of the effects of indapamide and captopril on the development of spontaneous hypertension. S Vrankova L Jendekova L Paulis M Sladkova F Simko O Pechanova, J Hypertens 2009 27 Suppl 6 42 6 S42-S46 10.1097/01.hjh.0000358837. 64052.0a 19633451
47. Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. I Bernatova O Pechanova V Pelouch F Simko, J Mol Cell Cardiol 2000 32 177 185 10.1006/jmcc.1999.1071 10722795
48. Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney. I Bernatova O Pechanova F Simko, Exp Physiol 1999 84 1095 1105 10.1017/S0958067099018904 10564706
49. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator- activated receptor-gamma. QN Diep MM El JS Cohn D Endemann F Amiri A Virdis MF Neves EL Schiffrin, Circulation 2002 105 2296 2302 10.1161/01.CIR.0000016049. 86468.23 12010913
50. Activation and suppression of renin-angiotensin system in human dendritic cells. N Lapteva K Ide M Nieda Y Ando Y Hatta-Ohashi M Minami G Dymshits K Egawa T Juji K Tokunaga, Biochem Biophys Res Commun 2002 296 194 200 10.1016/S0006-291X(02)00855-0 12147250
51. Vascular Angiotensin type 1 receptor expression is associated with vascular dysfunction, oxidative stress and inflammation in fructose-fed rats. MD Nyby K Abedi V Smutko P Eslami ML Tuck, Hypertens Res 2007 30 451 457 10.1291/hypres.30.451 17587757
52. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. R Kranzhofer M Browatzki J Schmidt W Kubler, Biochem Biophys Res Commun 1999 257 826 828 10.1006/bbrc.1999.0543 10208867
53. Angiotensin II-mediated signal transduction pathways. Y Saito BC Berk, Curr Hypertens Rep 2002 4 167 171 10.1007/s11906-002-0042-1 11884273
54. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. A Costanzo F Moretti VL Burgio C Bravi F Guido M Levrero PL Puri, J Cell Physiol 2003 195 402 410 10.1002/jcp.10191 12704649
55. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. C Savoia EL Schiffrin, Clin Sci (Lond) 2007 112 375 384 10.1042/CS20060247 17324119
56. Angiotensin II differentially regulates interleukin-1-beta-inducible NO synthase (iNOS) and vascular cell adhesion molecule-1 (VCAM-1) expression: role of p38 MAPK. B Jiang S Xu X Hou DR Pimentel RA Cohen, J Biol Chem 2004 279 20363 20368 10.1074/jbc.M314172200 15001568
57. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. DN Muller R Dechend EM Mervaala JK Park F Schmidt A Fiebeler J Theuer V Breu D Ganten H Haller FC Luft, Hypertension 2000 35 193 201 10642297
58. Renal NF-kappaB activation and TNF-alpha upregulation correlate with salt-sensitive hypertension in Dahl salt-sensitive rats. JW Gu N Tian M Shparago W Tan AP Bailey RD Manning Jr, Am J Physiol Regul Integr Comp Physiol 2006 291 1817 R1824 16840655
59. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. D Sanz-Rosa MP Oubina E Cediel HN de Las O Vegazo J Jimenez V Lahera V Cachofeiro, Am J Physiol Heart Circ Physiol 2005 288 111 H115 10.1152/ajpheart.01061.2003 15308481
60. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. PE Tummala XL Chen CL Sundell JB Laursen CP Hammes RW Alexander DG Harrison RM Medford, Circulation 1999 100 1223 1229 10484544
61. Rapid communication. Enalapril decreases nuclear factor kappa B activation in the kidney with urethral obstruction. JJ Morrissey S Klahr, Kidney Int 1997 52 926 933 10.1038/ki.1997.414 9328931
62. Renal sympathetic nerve responses to tempol in spontaneously hypertensive rats. T Shokoji A Nishiyama Y Fujisawa H Hitomi H Kiyomoto N Takahashi S Kimura M Kohno Y Abe, Hypertension 2003 41 266 273 10.1161/01.HYP.0000049621.85474.CF 12574093